柳叶刀_2012-June-29.pdf
Editorial Anewmilestoneinthehistoryofcongenitalheartdisease Andrew Ewer and colleagues meta-analysis of pulse hypoplastic left heart syndrome, but also to advance oximetry screening for critical congenital heart defects the possibility of intrauterine interventions that is a cheap and readily avail
Comment Quadsinitforantiretroviraltherapy? study teams assessed the efficacy and safety of the latest drug.Elvitegravir is metabolised mainly via CYP3A4-5, andsingle-tabletregimen—combining elvitegravir, cobicistat,which enables pharmacokinetic boosting and once- emtricitabine, and tenofovir
Comment Sax PE, Delesus E, Mills A, et al, forthe GS-US-236-0102 study team.Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, et al Tenofovir Co-formulated elvitegravir, cobicistat, emtricitabine, andtenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment nephro 
